Combination of compounds for treating or preventing skin diseases

Abstract

A combination of compounds for treating skin diseases and particularly rosacea and ocular rosacea is described. The combination of a compound of the avermectin family or of the mylbemycin family with a compound of the family of the alpha-1 or alpha-2 adrenergic receptor agonists is also described. In addition, a product in the form of a kit including: (a) a first composition containing a compound of the avermectin family or of the mylbemycin family, and (b) a second composition different from the first one and containing a compound of the family of the alpha-1 or alpha-2 adrenergic receptor agonists, as a combination product to be used as a drug for treating and/or preventing skin diseases and particularly rosacea and ocular rosacea, wherein said first and second compositions can be applied simultaneously, separately or with a time delay, is described.

1 - 32 . (canceled) 
     
     
         33 . A method for treating rosacea, the method comprising topically administering to a subject in need of such treatment, a first pharmaceutical composition comprising, in a physiologically acceptable medium, ivermectin in an amount of 0.01% to 5% by weight of the composition, and a second pharmaceutical composition comprising, in a physiologically acceptable medium, brimonidine or a salt thereof in an amount of from 0.01% to 5% by weight of the composition, the first composition being administered first and the second composition being administered thereafter, or the second composition being administered first and the first composition being administered thereafter, or both compositions being administered simultaneously. 
     
     
         34 . The method as claimed in  claim 33 , wherein the second pharmaceutical composition comprises, in a physiologically acceptable medium, brimonidine or brimonidine tartrate in an amount of from 0.01% to 5% by weight of the composition. 
     
     
         35 . The method as claimed in  claim 34 , wherein the ivermectin is present in an amount of 0.1%, 0.3% or 1% by weight of the composition. 
     
     
         36 . The method as claimed in  claim 33 , wherein the first pharmaceutical composition comprises, in a physiologically acceptable medium, ivermectin in an amount of 0.1%, 0.3% or 1% by weight of the composition, and the second pharmaceutical composition comprises, in a physiologically acceptable medium, brimonidine in an amount of 0.2% by weight of the composition.